SecBot SecBot

EW

Edwards Lifesciences Corp
NYSE· Orthopedic, Prosthetic & Surgical Appliances & Supplies· Inc. DE· CIK 0001099800 Healthcare & Medical Devices
$107.15 +1.35 (+1.28%)
Nov 13 4:00 PM ET · prev $105.80
Market cap
$60.8B
Large cap
Consensus
Buy
82% Buy or better · 39 analysts
Median target
$115.00
+7% · range $84.00–126.00
1 year
+26.4%
from $84.74 · Nov 17
30 days
+22.9%
from $87.22
52-week range
$75.87–107.15
at the high
Avg volume 20D
4.82M
Nov 2 spike 12.17M
Short interest
9.38M
≈1.6% of shares · +0.5%
Days to cover
2.8
at average volume
Insider net
−$18.7M
0 buyers · 7 sellers · since May 12
New fund stakes
5
Q3 2026 13F · 1 exit
Filing reports
27
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 0 bearish · 1 bullish · 10 neutral oldest → newest, height = score
Avg score ·High conf. 10/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $18.7M.

  • InstitutionsBULLISH

    Q3 2026: 54 added (5 new), 25 trimmed or exited. Largest new: Hrt Financial $19.6M, Lansforsakringar Fondforvaltning Ab (Publ) $16.2M.

  • AnalystsBULLISH

    32 of 39 rate it Buy or better. Median target $115.00 (+7%).

  • Short sellersSTEADY

    Short interest +0.5% to 9.38M shares. 2.8 days to cover, ≈1.6% of shares.

  • TrendUPTREND

    18% above its 50-day average. New closing high $107.15 on Nov 13.

Who's buying

13F· Q3 2026
5
new positions
1
exit
$46.7M
in new stakes · top 3 shown
FundMoveSharesValue
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD10,193,860$879.9M
FMR LLCTRIM6,099,846$526.5M
Invesco Ltd.ADD5,137,242$443.4M
Assenagon Asset Management S.A.ADD2,719,271$234.7M
BAILLIE GIFFORD & COADD1,740,553$150.2M
Zurcher Kantonalbank (Zurich Cantonalbank)DOUBLED1,422,110$122.8M
Qube Research & Technologies LtdDOUBLED1,331,753$115.0M
FRANKLIN TEMPLETON INCTRIM695,927$69.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

39 analysts
Buy 82% rate it Buy or better
Strong Buy13Buy19Hold7Sell0Strong Sell0
12-month targets · 27 analysts

Price is inside the target range. Median implies +7%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 11, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Nov 5, 2026UBS
MAINTAIN
MAINTAINBuy
Nov 5, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Nov 5, 2026Citigroup
MAINTAIN
MAINTAINBuy
Nov 5, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform

Washington

Corporate Lobbying

35 lobbying filings and 2 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$18.7M
sold · 7 insiders
DateInsiderTypeValue
Nov 13, 2026
Dahl Andrew M.
SVP, Corporate Controller
Nov 13, 2026
TAX W/H$10.7K
Nov 10, 2026
Lippis Daniel J.
CVP, TAVR
Nov 10, 2026
SELL$64.5K
Nov 10, 2026
Lippis Daniel J.
CVP, TAVR
Nov 10, 2026
EXERCISE$45.0K
Nov 9, 2026
Zovighian Bernard J
CEO
Nov 9, 2026
EXERCISE$1.7M
Nov 9, 2026
Zovighian Bernard J
CEO
Nov 9, 2026
SELL$949.5K
Nov 9, 2026
Zovighian Bernard J
CEO
Nov 9, 2026
SELL$1.4M
Nov 9, 2026
BOBO DONALD E JR
CVP,Strategy/Corp Development
Nov 9, 2026
SELL$5.0M
Nov 9, 2026
BOBO DONALD E JR
CVP,Strategy/Corp Development
Nov 9, 2026
EXERCISE$3.6M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Congressional trades
EW trades disclosed by members of Congress, with disclosure delay.
1 members · 3 buys / 0 sells
DateMemberType AmountDisclosed
May 27, 2026 Ro KhannaDHouse Spouse account · Edwards Lifesciences Corp BUY $1K–$15K Jun 9, 2026 +13d
May 15, 2026 Ro KhannaDHouse Spouse account · Edwards Lifesciences Corp BUY $1K–$15K Jun 9, 2026 +25d
May 1, 2026 Ro KhannaDHouse Child account · Edwards Lifesciences Corp BUY $1K–$15K Jun 9, 2026 +39d

Short side

FINRA· Oct 30, 2026
9,382,239
shares short
+0.5%
vs prior settlement
2.8
days to cover
≈1.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 Insider
Dahl Andrew M. surrendered for taxes 101 shares
SVP, Corporate Controller @ $105.80 ($10.7K)
Nov 10, 2026 SEC
Two Edwards Lifesciences insiders, including the CEO, executed open-market sales totaling $5.99M under 10b5-1 plans…
CLUSTER · Impact 2/10
Nov 10, 2026 SEC
Three Edwards Lifesciences insiders, including the CEO and a CVP, sold a total of $6.05M in open-market sales under…
CLUSTER · Impact 3/10
Nov 10, 2026 SEC
Daniel J. Lippis, an officer of Edwards Lifesciences, filed a Form 144 notice of intent to sell 1,857 shares of common…
144 · Impact 2/10
Nov 10, 2026 Insider
Lippis Daniel J. sold 619 shares
CVP, TAVR @ $104.25 ($64.5K)
Nov 10, 2026 Insider
Lippis Daniel J. acquired via exercise 619 shares
CVP, TAVR @ $72.68 ($45.0K)
Nov 4, 2026 Earnings result
EW Q3 2026 Earnings: EPS $0.8 (+5.4% vs est)
Sep 30, 2026 Inst.
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP · ADD
10,193,860 shares ($879.9M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 4, 2026
Earnings result
EW Q3 2026 Earnings: EPS $0.8 (+5.4% vs est)
Aug 10, 2026
Enforcement
Edwards Lifesciences, et al v. Thompson, et al
Court ruling (ca10), Docket: 25-01278
Jul 23, 2026
Earnings date
EW Q2 2026 Earnings After Market Close, 2026-07-23
Jul 13, 2026
Enforcement
FTC Secures $12 Million in Penalties for Pre-Merger Reporting Act Violations
FTC alleges Edwards Lifesciences and Genesis structured JC Medical deal to avoid federal antitrust review The Federal Trade Commission secured $12
May 13, 2026
Short interest
FTD: EW, 23,698 shares ($1.9M) failed to deliver
Settlement: 20260513, Price: $79.73, FTD Value: $1,889,441.54, EDWARDS LIFESCIENCES CORP

SecBot reports

27 filings · 3 bullish · 0 bearish · 24 neutral
All EW filing & press-release reports (27)